Frontlight ResearchEarly access
Neuroendocrine tumours trials in United States
89 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleStudy of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Where
- Charlottesville, Columbus, Iowa City, Jacksonville, Lexington, Los Angeles, Nashville, Phoenix, Portland, Rochester, Salt Lake City, St Louis
- Age
- 18 years and over
- People
- 104 worldwide
- Run by
- RayzeBio, Inc.
See details and how to joinNCT07165132 - Phase 2Taking peopleAdministration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- Where
- Bethesda
- Age
- 18 years to 72 years
- People
- 285
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT03412877 - Phase 2/3Taking peopleZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Where
- Albuquerque, Bethesda, Beverly Hills, Birmingham, Boston, Buffalo, Chapel Hill, Charlottesville, Cleveland, Columbus, Dallas, Detroit, Durham, Fairfax, Fargo, Grand Rapids, Jacksonville, Knoxville, Lexington, Los Angeles, Metairie, Milwaukee, Nashville, New York, Omaha, Orlando, Palo Alto, Philadelphia, Phoenix, Pittsburgh, Portland, Rochester, Salt Lake City, Santa Monica, Seattle, St Louis, Tampa, Tucson, Vallejo, Washington D.C.
- Age
- 18 years and over
- People
- 440 worldwide
- Run by
- Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00 - Phase 1Taking peoplePilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
- Where
- Boston
- Age
- 18 years and over
- People
- 30
- Run by
- Brigham and Women's Hospital
See details and how to joinNCT06062745 - Phase 2Taking people18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- Where
- Bethesda
- Age
- 18 years to 120 years
- People
- 320
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT06503146 - Phase 1Taking peopleAutologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
- Where
- Bethesda
- Age
- 18 years to 120 years
- People
- 40
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT07509034 - Phase 3Enrolling by invitationLong-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
- Where
- Bay Shore, Houston, Kettering, Memphis
- People
- 5,000
- Run by
- Exelixis
See details and how to joinNCT07620574 · EU 2026-525795-26-00 - No phaseTaking peopleA Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
- Where
- Sacramento
- Age
- 18 years and over
- People
- 9
- Run by
- University of California, Davis
See details and how to joinNCT05160480 - Phase 2Taking peopleLu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
- Where
- Bethesda
- Age
- 18 years to 100 years
- People
- 130
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT03206060 - Phase 1/2Taking peopleStudy of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
- Where
- Atlanta, Chicago, Cleveland, Glen Burnie, Houston, Omaha, Princeton, Tampa
- Age
- 18 years and over
- People
- 138
- Run by
- Molecular Partners AG
See details and how to joinNCT07278479 - Phase 1Taking peopleTesting the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
- Where
- City of Saint Peters, Creve Coeur, Duarte, Irvine, Orange, Shiloh, St Louis
- Age
- 18 years and over
- People
- 24 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT05687123 - Phase 2Not yet taking people in United StatesTemozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
- Where
- Buffalo
- Age
- 18 years and over
- People
- 60
- Run by
- Roswell Park Cancer Institute
See details and how to joinNCT06202066 - No phaseTaking peopleTissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
- Where
- Bethesda
- Age
- 18 years and over
- People
- 2,000
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT02146170 - Phase 2Taking peopleNatural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- Where
- Bethesda
- Age
- 12 years and over
- People
- 740
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT04074135 - Phase 1/2Taking peopleLu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
- Where
- Bethesda
- Age
- 18 years to 100 years
- People
- 56
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT04086485 - Phase 1/2Taking peopleSomatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
- Where
- Bethesda
- Age
- 18 years to 120 years
- People
- 66
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT06427798 - Phase 1Taking peopleA First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- Where
- Dallas, Hackensack, Houston, Nashville, New York, Seattle, St Louis
- Age
- 18 years and over
- People
- 110
- Run by
- Moonlight Bio, Inc
See details and how to joinNCT07488923 - No phaseTaking peopleA Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
- Where
- East Hanover
- Age
- 18 years to 110 years
- People
- 4,023
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07635316 - Phase 2Taking peopleZanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
- Where
- Rochester, St Louis
- Age
- 18 years and over
- People
- 32
- Run by
- Washington University School of Medicine
See details and how to joinNCT06926634 - Phase 1/2Taking peopleTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Where
- Baltimore, Chapel Hill, Chicago, Cleveland, Columbus, Detroit, Fairfax, Grand Rapids, Iowa City, Jacksonville, Lexington, Miami, Milwaukee, Nashville, Omaha, Orlando, Rochester, Seattle, St Louis, Troy
- Age
- 18 years to 90 years
- People
- 300
- Run by
- Perspective Therapeutics
See details and how to joinNCT05636618 - No phaseEnrolling by invitationEndoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms
- Where
- Columbus
- Age
- 18 years and over
- People
- 12
- Run by
- Ohio State University Comprehensive Cancer Center
See details and how to joinNCT07619417 - Phase 2Taking peopleCapTemY90 for Grade 2/3 NET Liver Metastases
- Where
- Buffalo, La Jolla, Miami, Philadelphia
- Age
- 18 years and over
- People
- 70
- Run by
- Abramson Cancer Center at Penn Medicine
See details and how to joinNCT04339036 - Phase 1Not yet taking people in United States211At-MABG in Adults With Advanced Neuroendocrine Cancers
- Where
- Philadelphia
- Age
- 18 years and over
- People
- 16
- Run by
- University of Pennsylvania
See details and how to joinNCT07661420 - Phase 1Taking people[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
- Where
- Bethesda
- Age
- 18 years to 120 years
- People
- 120
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT06479811 - Phase 1/2Taking peopleRadiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- Where
- Gilbert, Seattle, Tucson
- Age
- 18 years to 99 years
- People
- 30
- Run by
- University of Arizona
See details and how to joinNCT06814496